

UNITED THERAPEUTICS Corp  
Form 4  
May 16, 2016

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ZACCARDELLI DAVID

2. Issuer Name and Ticker or Trading Symbol  
UNITED THERAPEUTICS Corp  
[UTHR]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
05/13/2016

\_\_\_\_ Director  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
EVP & Chief Operating Officer

C/O UNITED THERAPEUTICS  
CORP., 1040 SPRING STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SILVER SPRING, MD 20910

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |            |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|-----------------------------------|------------|-------|
|                                 |                                      |  |                                | Code  | V | Amount |   |  |                                   | (A) or (D) | Price |
| Common Stock                    | 05/13/2016                           |  | M <sup>(1)</sup>               |   |   | 10,750 | A   | \$ 47.5  | 12,292                            | D          |       |
| Common Stock                    | 05/13/2016                           |  | M <sup>(1)</sup>               |   |   | 11,500 | A   | \$ 61.06   | 23,792                            | D          |       |
| Common Stock                    | 05/13/2016                           |  | M <sup>(1)</sup>               |   |   | 64,000 | A   | \$ 65.8  | 87,792                            | D          |       |
| Common Stock                    | 05/13/2016                           |  | M <sup>(1)</sup>               |   |   | 25,000 | A   | \$ 94.96   | 112,792                           | D          |       |
| Common Stock                    | 05/13/2016                           |  | D <sup>(1)</sup>               |   |   | 10,750 | D   | \$ 111.48  | 102,042                           | D          |       |

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

|              |            |                  |        |   |           |        |   |
|--------------|------------|------------------|--------|---|-----------|--------|---|
| Common Stock | 05/13/2016 | D <sup>(1)</sup> | 11,500 | D | \$ 111.48 | 90,542 | D |
| Common Stock | 05/13/2016 | D <sup>(1)</sup> | 64,000 | D | \$ 111.48 | 26,542 | D |
| Common Stock | 05/13/2016 | D <sup>(1)</sup> | 25,000 | D | \$ 111.48 | 1,542  | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Share Tracking Award                       | \$ 47.5  | 05/13/2016                           |  | M <sup>(1)</sup>               | 10,750  | 03/15/2013 03/15/2022                                    | Common Stock 10,750   |
| Share Tracking Award                       | \$ 61.06   | 05/13/2016                           |  | M <sup>(1)</sup>               | 11,500  | 03/15/2014 03/15/2023                                    | Common Stock 11,500   |
| Share Tracking Award                       | \$ 65.8  | 05/13/2016                           |  | M <sup>(1)</sup>               | 64,000  | 03/15/2012 03/15/2021                                    | Common Stock 64,000   |
| Share Tracking Award                       | \$ 94.96   | 05/13/2016                           |  | M <sup>(1)</sup>               | 25,000  | 03/14/2015 03/14/2024                                    | Common Stock 25,000   |

## Reporting Owners

| Reporting Owner Name / Address                     | Relationships |           |                       |       |
|--|---------------|-----------|-----------------------|-------|
|  | Director      | 10% Owner | Officer               | Other |
| ZACCARDELLI DAVID<br>C/O UNITED THERAPEUTICS CORP. |               |           | EVP & Chief Operating |       |

1040 SPRING STREET  
SILVER SPRING, MD 20910

Officer

## Signatures

/s/ John S. Hess, Jr. under Power of  
Attorney

05/16/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercise of a cash-settled share tracking award pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.